5 Results for "

targets CD79b

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "targets CD79b" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99042
CAS No.: 2279068-37-8
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132253
CAS No.: 1313206-42-6
Purity:  98.83%
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132253A
CAS No.: 1313206-42-6
Purity:  98.36%
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
loading...
    loading...
Cat. No.: HY-P991086
Synonyms: PRV-3279

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P991671
CAS No.: 3009026-69-8
Synonyms: JNJ-80948543

Research Areas:  

Cancer

Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
loading...
    loading...